Errors in Results Section

In the Original Investigation titled “Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial,”1 published in the September issue of JAMA Dermatology, all of the P values at week 24 in the last paragraph of the “Efficacy Outcomes” subsection of the Results section have now been included as a part of the primary output of the trial because they were part of the prespecified analyses, and the percentage of 205 of 344 dupilumab-treated patients should be 59.5%, not 59.2%. Also, more data were added to eTable 5 in Supplement 2. This article has been corrected online.

1.Blauvelt  A, Teixeira  HD, Simpson  EL, et al.  Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial.   JAMA Dermatol. 2021;157(9):1047-1055. doi:10.1001/jamadermatol.2021.3023PubMedGoogle Scholar

留言 (0)

沒有登入
gif